Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro
Alzheimer’s disease (AD) and Parkinson’s disease (PD), including dementia with Lewy bodies (DLB), account for the majority of dementia cases worldwide. Interestingly, a significant number of patients have clinical and neuropathological features of both AD and PD, i.e., the presen...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/3/580 |
id |
doaj-7da9d0773fc1416584614e4190644c3e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Janett Köppen Anja Schulze Lisa Machner Michael Wermann Rico Eichentopf Max Guthardt Angelika Hähnel Jessica Klehm Marie-Christin Kriegeskorte Maike Hartlage-Rübsamen Markus Morawski Stephan von Hörsten Hans-Ulrich Demuth Steffen Roßner Stephan Schilling |
spellingShingle |
Janett Köppen Anja Schulze Lisa Machner Michael Wermann Rico Eichentopf Max Guthardt Angelika Hähnel Jessica Klehm Marie-Christin Kriegeskorte Maike Hartlage-Rübsamen Markus Morawski Stephan von Hörsten Hans-Ulrich Demuth Steffen Roßner Stephan Schilling Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro Molecules alpha-synuclein (α-synuclein) alzheimer’s disease amyloid-beta (aβ) dementia with lewy bodies parkinson’s disease |
author_facet |
Janett Köppen Anja Schulze Lisa Machner Michael Wermann Rico Eichentopf Max Guthardt Angelika Hähnel Jessica Klehm Marie-Christin Kriegeskorte Maike Hartlage-Rübsamen Markus Morawski Stephan von Hörsten Hans-Ulrich Demuth Steffen Roßner Stephan Schilling |
author_sort |
Janett Köppen |
title |
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro |
title_short |
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro |
title_full |
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro |
title_fullStr |
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro |
title_full_unstemmed |
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro |
title_sort |
amyloid-beta peptides trigger aggregation of alpha-synuclein in vitro |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2020-01-01 |
description |
Alzheimer’s disease (AD) and Parkinson’s disease (PD), including dementia with Lewy bodies (DLB), account for the majority of dementia cases worldwide. Interestingly, a significant number of patients have clinical and neuropathological features of both AD and PD, i.e., the presence of amyloid deposits and Lewy bodies in the neocortex. The identification of α-synuclein peptides in amyloid plaques in DLB brain led to the hypothesis that both peptides mutually interact with each other to facilitate neurodegeneration. In this article, we report the influence of Aβ(1−42) and pGlu-Aβ(3−42) on the aggregation of α-synuclein in vitro. The aggregation of human recombinant α-synuclein was investigated using thioflavin-T fluorescence assay. Fibrils were investigated by means of antibody conjugated immunogold followed by transmission electron microscopy (TEM). Our data demonstrate a significantly increased aggregation propensity of α-synuclein in the presence of minor concentrations of Aβ(1−42) and pGlu-Aβ(3−42) for the first time, but without effect on toxicity on mouse primary neurons. The analysis of the composition of the fibrils by TEM combined with immunogold labeling of the peptides revealed an interaction of α-synuclein and Aβ in vitro, leading to an accelerated fibril formation. The analysis of kinetic data suggests that significantly enhanced nucleus formation accounts for this effect. Additionally, co-occurrence of α-synuclein and Aβ and pGlu-Aβ, respectively, under pathological conditions was confirmed in vivo by double immunofluorescent labelings in brains of aged transgenic mice with amyloid pathology. These observations imply a cross-talk of the amyloid peptides α-synuclein and Aβ species in neurodegeneration. Such effects might be responsible for the co-occurrence of Lewy bodies and plaques in many dementia cases. |
topic |
alpha-synuclein (α-synuclein) alzheimer’s disease amyloid-beta (aβ) dementia with lewy bodies parkinson’s disease |
url |
https://www.mdpi.com/1420-3049/25/3/580 |
work_keys_str_mv |
AT janettkoppen amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT anjaschulze amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT lisamachner amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT michaelwermann amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT ricoeichentopf amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT maxguthardt amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT angelikahahnel amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT jessicaklehm amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT mariechristinkriegeskorte amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT maikehartlagerubsamen amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT markusmorawski amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT stephanvonhorsten amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT hansulrichdemuth amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT steffenroßner amyloidbetapeptidestriggeraggregationofalphasynucleininvitro AT stephanschilling amyloidbetapeptidestriggeraggregationofalphasynucleininvitro |
_version_ |
1724696149013561344 |
spelling |
doaj-7da9d0773fc1416584614e4190644c3e2020-11-25T03:00:54ZengMDPI AGMolecules1420-30492020-01-0125358010.3390/molecules25030580molecules25030580Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In VitroJanett Köppen0Anja Schulze1Lisa Machner2Michael Wermann3Rico Eichentopf4Max Guthardt5Angelika Hähnel6Jessica Klehm7Marie-Christin Kriegeskorte8Maike Hartlage-Rübsamen9Markus Morawski10Stephan von Hörsten11Hans-Ulrich Demuth12Steffen Roßner13Stephan Schilling14Fraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyFraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyFraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyFraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyFraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyFraunhofer Institute of Cell Therapy and Immunology IZI, 04103 Leipzig, GermanyFraunhofer Institute for Microstructure of Materials and Systems IMWS, 06120 Halle, GermanyFraunhofer Institute for Microstructure of Materials and Systems IMWS, 06120 Halle, GermanyPaul Flechsig Institute of Brain Research, University of Leipzig, 04109 Leipzig, GermanyPaul Flechsig Institute of Brain Research, University of Leipzig, 04109 Leipzig, GermanyPaul Flechsig Institute of Brain Research, University of Leipzig, 04109 Leipzig, GermanyFriedrich-Alexander-University Erlangen-Nürnberg, Preclinical Experimental Center, 91054 Erlangen, GermanyFraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyPaul Flechsig Institute of Brain Research, University of Leipzig, 04109 Leipzig, GermanyFraunhofer Institute of Cell Therapy and Immunology, Department of Drug Design and Target Validation IZI-MWT, 06120 Halle, GermanyAlzheimer’s disease (AD) and Parkinson’s disease (PD), including dementia with Lewy bodies (DLB), account for the majority of dementia cases worldwide. Interestingly, a significant number of patients have clinical and neuropathological features of both AD and PD, i.e., the presence of amyloid deposits and Lewy bodies in the neocortex. The identification of α-synuclein peptides in amyloid plaques in DLB brain led to the hypothesis that both peptides mutually interact with each other to facilitate neurodegeneration. In this article, we report the influence of Aβ(1−42) and pGlu-Aβ(3−42) on the aggregation of α-synuclein in vitro. The aggregation of human recombinant α-synuclein was investigated using thioflavin-T fluorescence assay. Fibrils were investigated by means of antibody conjugated immunogold followed by transmission electron microscopy (TEM). Our data demonstrate a significantly increased aggregation propensity of α-synuclein in the presence of minor concentrations of Aβ(1−42) and pGlu-Aβ(3−42) for the first time, but without effect on toxicity on mouse primary neurons. The analysis of the composition of the fibrils by TEM combined with immunogold labeling of the peptides revealed an interaction of α-synuclein and Aβ in vitro, leading to an accelerated fibril formation. The analysis of kinetic data suggests that significantly enhanced nucleus formation accounts for this effect. Additionally, co-occurrence of α-synuclein and Aβ and pGlu-Aβ, respectively, under pathological conditions was confirmed in vivo by double immunofluorescent labelings in brains of aged transgenic mice with amyloid pathology. These observations imply a cross-talk of the amyloid peptides α-synuclein and Aβ species in neurodegeneration. Such effects might be responsible for the co-occurrence of Lewy bodies and plaques in many dementia cases.https://www.mdpi.com/1420-3049/25/3/580alpha-synuclein (α-synuclein)alzheimer’s diseaseamyloid-beta (aβ)dementia with lewy bodiesparkinson’s disease |